NCT05751733View on ClinicalTrials.gov

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

NARecruitingINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Apatinib Mesylate

Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect of anti-C-Kit and PDGFR.

DRUG

Sunitinib, Imatinib dosage, Dasatinib, Reveratinib

Second-line TKI drugs

Trial Locations (1)

410013

RECRUITING

Xiangya Hospital, Central South University, Changsha

All Listed Sponsors
collaborator

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

lead

Xiangya Hospital of Central South University

OTHER